Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|October 19, 2023

Expert Perspectives on the VIOLETTE Study and Future Directions in Prostate Cancer Research

Author(s)Amir H. Lebastchi, MD

Amir H. Lebastchi, MD, provides perspectives on the VIOLETTE study and underscores the importance of future head-to-head trials to gain a deeper understanding of various treatment approaches.

Episodes in this series

Amir H. Lebastchi, MD, an expert on prostate cancer

EP. 1 Landscape Surrounding Prostate Cancer Screening

Amir H. Lebastchi, MD, an expert on prostate cancer

EP. 2 Updates in Approaches for Prostate Cancer Biopsy and Diagnosis

Amir H. Lebastchi, MD, an expert on prostate cancer

EP. 3 The Evolving Landscape Surrounding Fusion-Guided Prostate Biopsy

Amir H. Lebastchi, MD, an expert on prostate cancer

EP. 4 Perspectives on Comparative Data for Software- and Cognitive-Based Fusion Biopsies

Amir H. Lebastchi, MD, an expert on prostate cancer

EP. 5 Leveraging MRI and Fusion-Guided Biopsy for Active Surveillance in Prostate Cancer

Amir H. Lebastchi, MD, an expert on prostate cancer

EP. 6 Integrating MRI and Ultrasound Fusion-Based Technology for Personalized Focal Therapy in Prostate Cancer

Amir H. Lebastchi, MD, an expert on prostate cancer

EP. 7 Expert Perspectives on the VIOLETTE Study and Future Directions in Prostate Cancer Research

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Jamie Michael, MD, discusses MRI and genomics in active surveillance

ByJamie Michael, MD

July 16th 2026

Study to assess adaptive-dosed 177Lu-DOTA-HYNIC-panPSMA in mHSPC

ByHannah Clarke

July 16th 2026

Pivotal phase 3 trial launches of rinzimetostat plus darolutamide in mCRPC

ByHannah Clarke

July 15th 2026

Genomic Prostate Score may help refine risk assessment in localized prostate cancer

ByHannah Clarke

July 14th 2026

Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer

ByDaniel J. George, MD

July 13th 2026

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation

Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC

First-in-human bladder transplant demonstrates sustained function at 6 months

Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC

Department of Defense announces annual testosterone deficiency screening for service members